1. Metabolic Enzyme/Protease Apoptosis Anti-infection Autophagy
  2. Cytochrome P450 Apoptosis Bacterial Autophagy
  3. Acetylshikonin

Acetylshikonin  (Synonyms: 乙酰紫草素)

目录号: HY-N2181 纯度: 99.39%
COA 产品使用指南

Acetylshikonin 是口服有效的抗癌、抗炎、抗氧化、抗生育、抑菌和神经保护剂。Acetylshikonin 是乙酰胆碱酶 (AChE) (IC50=34.6 μM) 和非选择性的细胞色素 P450 的抑制剂。Acetylshikonin 能够诱导癌细胞凋亡自噬。Acetylshikonin 可以调节血糖、肝脂肪代谢和肾纤维化,用于糖尿病、糖尿病肾病 (DN)、肥胖、非酒精性脂肪肝 (NAFLD) 的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Acetylshikonin Chemical Structure

Acetylshikonin Chemical Structure

CAS No. : 24502-78-1

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥825
In-stock
5 mg ¥750
In-stock
10 mg ¥1200
In-stock
25 mg ¥2350
In-stock
50 mg ¥3550
In-stock
100 mg ¥5350
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Acetylshikonin:

MCE 顾客使用本产品发表的 1 篇科研文献

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC50=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD)[1][2][3][4][5][6][7][8][9].

IC50 & Target

AChE

 

体外研究
(In Vitro)

Acetylshikonin(1.6-100 μM) 抑制口腔癌细胞 KB-R5 的增殖 IC50 为 40 μM[6]
Acetylshikonin (20-80 μM; 24 h) 可以诱导 KB-R5 细胞凋亡和 (20-80 μM) 自噬,并且阻断了 KB-R5 细胞中 mTOR/PI3K/AKT 信号通路[6]
Acetylshikonin (1-10 μM; 12 h) 可以通过上调血红素氧合酶-1 来抑制 H2O2 (500 μM; 4 h)诱导的成神经细胞瘤 SH-SY5Y 和 pc12 细胞凋亡[8]
Acetylshikonin (0.01-5 μM/L; 2 h) 在吸附/侵入阶段具有抗 Coxsackievirus A16 (CVA16) 活性,EC50 为 0.04 μmol/L,但在病毒感染前、复制和释放阶段无效[2]
Acetylshikonin (0.01-1 μM; 30 min) 通过 PLC-β3/PKCδ 介导促进骨骼肌细胞 L6 摄取葡萄糖从而降低血糖水平[3]
Acetylshikonin (1-5 μg/mL); 48 h) 在 HK2 细胞可以抑制 TGF-β1 (5 ng/mL) 诱导肾纤维化[5]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[6]

Cell Line: KB-R5 (oral cancer cell line)
Concentration: 20 μM, 40 μM, 80 μM
Incubation Time: 24 h
Result: Changed the morphology of the nucleus.
Increased apoptosis ratio.

Western Blot Analysis[6]

Cell Line: KB-R5 (oral cancer cell line)
Concentration: 20 μM, 40 μM, 80 μM
Incubation Time:
Result: Increased the expression of Beclin-1 and LC3-II and inhibited the expression of p62. However, had no effect on the expression of LC3-I and Vps34.
Decreased the expression of p-mTOR, p-PI3K and p-AKT in a concentration-dependent manner.

Cell Viability Assay[2]

Cell Line: CVA16-induced human rhabdomyosarcoma (RD) cells
Concentration: 0.01-5 μM/L (1:1 mix with CVA16 strain TA271)
Incubation Time: 2 h
Result: Reduced CVA16-induced cytopathic effect with inhibition rates of 80% at the concentration of 0.08 μmol/L.

Western Blot Analysis[3]

Cell Line: L6 (rat skeletal muscle cells)
Concentration: 0.01 μM, 0.1 μM, 1 μM
Incubation Time: 2 h
Result: Significantly up-regulated phosphorylation of PKCδ.
Up-regulates the expression of glucose transporter 4 (GLUT4).and PLC-β3.
体内研究
(In Vivo)

Acetylshikonin ( 50 mg/kg; 腹腔注射; 每周三次连续 6 周) 以浓度依赖方式显著抑制 BALB/c 裸鼠的肿瘤生长[6]
Acetylshikonin (270-1080 mg/kg; 灌胃给药; 一天一次连续30 天) 通过降低小鼠氧化应激和神经炎症,抑制 p53/p21 信号通路的激活,来减轻 d-半乳糖诱导 (150 mg/kg) 的认知障碍和海马衰老[1]
Acetylshikonin (2 mg/kg; 肌肉注射; 单剂量) 抑制柯萨基病毒 16 (CVA16) 在小鼠中复制[2]
Acetylshikonin (100 mg/kg; 灌胃给药; 一天一次连续八周 ) 在链脲佐菌素 (STZ) 诱导糖尿病 C57BL/6 小鼠中可以在不影响血糖的情况下,通过抑制 TGF-β1/Smad 通路来有效抑制肾纤维化,减轻肾功能的损害[5]
Acetylshikonin (10 mk/kg; 腹腔注射; 一天一次连续三天) 降低了四氧嘧啶 (180 mg/kg; 腹腔注射; 单剂量) 诱导的糖尿病小鼠的血糖水平[3]
Acetylshikonin (540 mg/kg; 口服给药; 一天一次连续八周) 通过调节肥胖 C57BL/6J 小鼠的脂肪代谢和肝脏炎症,来减少肝脏脂肪堆积,从而改善肥胖和非酒精性脂肪肝 (NAFLD)[4]
Acetylshikonin (120-1080 mg/kg; 灌胃给药; ) 在 Sprague-Dawley 大鼠中低剂量时 (120 mg/kg 和 360 mg/kg) 不影响妊娠能力,在高剂量时 (1080 mg/kg) 可以通过影响促性腺激素 (GTH) 的分泌过程,降低血清促卵泡激素 (FSH) 和黄体生成素 (LH) 水平,从而抑制大鼠的妊娠能力[7]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: D-galactose (D-gal)-induced sub-acuteaging mouse model of Alzheimer’s disease (AD)[1]
Dosage: 270 mg/kg, 540 mg/kg, 1080 mg/kg
Administration: Intragastrical administration (i.g.); Once daily for 30 days. After D-gal treatment (150 mg/kg; Subcutaneous injection (s.c.); Once daily for 30 days)
Result: Decreased levels of the pro-inflammatory cytokines IL-1β and TNF-α.
Decreased the content of MDA and increased the activity of SOD.
Significantly mitigated D-Gal-induced downregulation of SIRT1 in hippocampal neurons.
Significantly inhibited the expression of p53, acetyl-p53, and p21 in mice (all proteins associated with hippocampal aging).
Animal Model: CAV16-indeced ICR suckling mice model[2]
Dosage: 2 mg/kg
Administration: Intramuscular injection (i.m.); Single dose. After CVA16 treatment (10[5.5] TCID50/g; Intramuscular injection (i.m.); Single dose )
Result: Delayed death of the mice (6 days post-infection and 7 dpi), and eventually resulted in a survival rate of 50% and 70% for the mice in the treatment and prevention groups, respectively (the death of the control mice began at 4 days after infection and all died at 6 days after infection).
Animal Model: Obese male C57BL/6J Mice model[4]
Dosage: 540 mg/kg
Administration: Oral gavage (P.O.); Once daily for 8 weeks
Result: Reduced body mass index (BMI) and food efficiency in obese mice by 17.1% and 48.2%, respectively.
Decreased plasma glucose, CHE, AST and ALT levels by 34.1%, 45.5% and 27.2%, respectively.
Significantly inhibited the levels of serum proinflammatory cytokines TNF-α, IL-6 and IL-1β by 49.1%, 41.1% and 45.6%, respectively.
分子量

330.33

Formula

C18H18O6

CAS 号
性状

固体

颜色

Brown to khaki

中文名称

乙酰紫草素

结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO 中的溶解度 : 50 mg/mL (151.36 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.0273 mL 15.1364 mL 30.2728 mL
5 mM 0.6055 mL 3.0273 mL 6.0546 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

In Vivo:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (7.57 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    20% SBE-β-CD in Saline 的配制(4°C,储存一周):2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
请输入您的动物体内配方组成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠,建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括:DMSO ,均可在 MCE 网站选购。 Tween 80,均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO(母液浓度为 mg/mL)。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的储备液浓度超过该产品的实测溶解度,以下方案仅供参考,如有需要,请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液,加入 μL  μL ,混合均匀至澄清,再加 μL Tween 80,混合均匀至澄清,再加 μL 生理盐水
连续给药周期超过半月以上,请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态,从左到右依次添加助溶剂。您可采用超声加热 (超声清洗仪,建议频次 20-40 kHz),涡旋吹打等方式辅助溶解。
纯度 & 产品资料

纯度: 99.39%

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.0273 mL 15.1364 mL 30.2728 mL 75.6819 mL
5 mM 0.6055 mL 3.0273 mL 6.0546 mL 15.1364 mL
10 mM 0.3027 mL 1.5136 mL 3.0273 mL 7.5682 mL
15 mM 0.2018 mL 1.0091 mL 2.0182 mL 5.0455 mL
20 mM 0.1514 mL 0.7568 mL 1.5136 mL 3.7841 mL
25 mM 0.1211 mL 0.6055 mL 1.2109 mL 3.0273 mL
30 mM 0.1009 mL 0.5045 mL 1.0091 mL 2.5227 mL
40 mM 0.0757 mL 0.3784 mL 0.7568 mL 1.8920 mL
50 mM 0.0605 mL 0.3027 mL 0.6055 mL 1.5136 mL
60 mM 0.0505 mL 0.2523 mL 0.5045 mL 1.2614 mL
80 mM 0.0378 mL 0.1892 mL 0.3784 mL 0.9460 mL
100 mM 0.0303 mL 0.1514 mL 0.3027 mL 0.7568 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Acetylshikonin
目录号:
HY-N2181
需求量: